抗体结合向纳米疗法在表观遗传上抑制了calpain介导的线粒体功能障碍,以减轻帕金森病的发生
Liku Biswal1, Vikas Kumar Sahu1, Mohammed Nadim Sardoiwala1
1Epigenetics Research Laboratory, Institute of Nano Science and Technology, Knowledge City, Sector 81, Mohali, Punjab 140306, India.
Carbohydrate polymers
|September 8, 2024
概括
使用纳米粒子向向大脑输送17β-雌激醇 (E2),通过抑制calpain和促进线粒体中的BMI1,改善了帕金森病 (PD) 治疗. 这种方法提高了细胞活力和线粒体功能,为神经治疗提供了好处.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 与17β-雌激醇 (E2) 不平衡和线粒体功能障碍有关.
- 周围的副作用和不清楚的机制限制了E2在PD的神经治疗用途.
研究的目的:
- 为E2开发一个有针对性的脑传递系统,以克服PD治疗的局限性.
- 阐明E2涉及线粒体中calpain和BMI1的神经保护作用的分子机制.
主要方法:
- 带有E2的奇托桑纳米颗粒与多巴胺受体D3 (DRD3) 结合,用于对大脑进行向 (Ab-ECSnps).
- 在体外评估calpain和BMI1转位,细胞活力,线粒体DNA拷贝数和膜潜力.
- 在PD模型中对Ab-ECSnps的体内评估.
主要成果:
- Ab-ECSnps证明了有效的脑传递和抑制线粒体calpain转位.
- 服用Ab-ECSnps促进了BMI1转移到线粒体,增强了细胞活力和线粒体功能.
- 对线粒体恒温的calpain介导BMI1调节的新型机制被确定,在体内PD模型中显示治疗潜力.
结论:
- 通过Ab-ECSnps对E2的向输送通过维护线粒体平衡为PD治疗提供了一个有希望的策略.
- 这项研究揭示了一种涉及calpain和BMI1的新型分子途径,用于减轻PD病理.
相关概念视频
01:24Parkinson's Disease: Treatment
237
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
237
01:46Electron Transport Chain: Complex I and II
12.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.2K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:15Parkinson's Disease: Overview
498
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
498
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170